Target intelligence / Profile preview

Growth-associated protein 43 (GAP-43)

Target
GAP-43
Molecular classification
Other (neuron-specific membrane-associated phosphoprotein), Adaptor protein, not an enzyme/receptor/transporter
01

Overview

Growth-associated protein 43 (GAP-43) is a neuron-specific, membrane-associated phosphoprotein crucial for axonal outgrowth, synaptic plasticity, and neural regeneration. Highly expressed during development and after neuronal injury, GAP-43 is associated with the presynaptic membrane, influencing actin cytoskeleton remodeling, axon guidance, dendrite formation, and memory function. It serves as a substrate for protein kinase C (PKC) and binds calmodulin and phospholipids, functioning as an adaptor protein at nerve terminals. Changes in GAP-43 expression or function have been linked to neurodevelopmental disorders, epilepsy, and neurodegenerative diseases such as Alzheimer’s, where it is also being explored as a biomarker for disease progression and synaptic integrity. GAP-43 mutations or dysregulation result in defective neural connectivity and severe developmental phenotypes.

Other names
protein F1neuromodulinneural phosphoprotein B-50axonal membrane protein GAP-43calmodulin-binding protein P-57nerve growth-related peptide GAP43neuron growth-associated protein 43Basp2pp46
02

Mechanism of action

In preclinical models, DHF increases GAP-43 expression, believed to improve neuronal survival and reduce pathology by mimicking BDNF signaling. Drugs targeting PKC can indirectly modulate GAP-43 function through its phosphorylation in neurons.

03

Biological functions

Axonal growth and pathfindingNeuronal developmentSynaptic plasticityMemory and learningRegeneration after injuryDendritic arbor formationBinding and regulation of the actin cytoskeleton
04

Disease associations

Neurodevelopmental disordersIntellectual disabilityEpilepsyAlzheimer’s diseaseNeurodegenerative diseases in general
05

Safety considerations

Not directly druggable, but manipulation may perturb normal neuronal development and plasticity, potentially leading to cognitive dysfunction or exacerbation of neurological disorders if not tightly controlled
06

Interacting drugs

7,8-dihydroxyflavone (DHF, a brain-derived neurotrophic factor (BDNF) mimetic upregulating GAP-43 in model systems)
07

Biomarkers

Elevated GAP-43 in the brain, cerebrospinal fluid (CSF), or serum is considered a biomarker of synaptic plasticity, axonal growth, and neurodegeneration (especially in Alzheimer's disease and epilepsy)

Beyond the preview

Go deeper on Growth-associated protein 43 (GAP-43).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Growth-associated protein 43 (GAP-43).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call